Clearmind Medicine (CMND) announced that the United States Patent Office has issued a Notice of Allowance for a patent relating to its MEAI treatment for binge behavior. This new US patent provides additional intellectual property protection for the Company’s novel MEAI- based treatment in this indication and further strengthens Clearmind’s intellectual property portfolio.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMND:
- Clearmind Medicine launches first U.S. clinical site for AUD trial
- Psychedelic: Clearmind initiates U.S. clinical site for CMND-100 trial
- Clearmind Medicine announces U.S. clinical site initiation for CMND-100 trial
- Clearmind announces patent application for psychedelic-based compounds
- Psychedelic: Enveric, Filament Health report earnings results